Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shanu Modi

Showing results (1-10 of 114) with videos related to

Pageof 12
Sort By:
Future Oncology (London, England)|January 9, 2025
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 studyShanu Modi
Future Oncology (London, England)|July 15, 2021
Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 studyShanu Modi
Oncotargets and Therapy|August 6, 2015
Ganetespib: research and clinical developmentKomal Jhaveri, Shanu Modi
JAMA|December 13, 2007
Preoperative chemotherapy for breast cancer: miracle or mirage?Clifford Hudis, Shanu Modi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?Sarat Chandarlapaty, Shanu Modi
Nature Reviews. Clinical Oncology|November 6, 2024
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?Joshua Drago, Shanu Modi
Advances in Pharmacology (San Diego, Calif.)|September 11, 2012
HSP90 inhibitors for cancer therapy and overcoming drug resistanceKomal Jhaveri, Shanu Modi
Biologics : Targets & Therapy|August 27, 2009
HER2 breast cancer therapies: a reviewConleth G Murphy, Shanu Modi
Clinical Breast Cancer|February 3, 2004
Single-agent gemcitabine in the treatment of advanced breast cancerShanu Modi, Andrew D Seidman
Current Oncology Reports|December 6, 2001
An update on epidermal growth factor receptor inhibitorsShanu Modi, Andrew D Seidman
Pageof 12

Showing results (1-10 of 114) with videos related to

Sort By:
Pageof 12
Future Oncology (London, England)|January 9, 2025
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 studyShanu Modi
Future Oncology (London, England)|July 15, 2021
Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 studyShanu Modi
Oncotargets and Therapy|August 6, 2015
Ganetespib: research and clinical developmentKomal Jhaveri, Shanu Modi
JAMA|December 13, 2007
Preoperative chemotherapy for breast cancer: miracle or mirage?Clifford Hudis, Shanu Modi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?Sarat Chandarlapaty, Shanu Modi
Nature Reviews. Clinical Oncology|November 6, 2024
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?Joshua Drago, Shanu Modi
Advances in Pharmacology (San Diego, Calif.)|September 11, 2012
HSP90 inhibitors for cancer therapy and overcoming drug resistanceKomal Jhaveri, Shanu Modi
Biologics : Targets & Therapy|August 27, 2009
HER2 breast cancer therapies: a reviewConleth G Murphy, Shanu Modi
Clinical Breast Cancer|February 3, 2004
Single-agent gemcitabine in the treatment of advanced breast cancerShanu Modi, Andrew D Seidman
Current Oncology Reports|December 6, 2001
An update on epidermal growth factor receptor inhibitorsShanu Modi, Andrew D Seidman
Pageof 12